Conventional dosing of anticancer agents: Precisely wrong or just inaccurate?

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 361-364

  Bins, S ^a   Ratain, M J ^b   Mathijssen, R H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; IRINOTECAN; PACLITAXEL;

ACCURACY; BODY HEIGHT; BODY SIZE; BODY SURFACE; BODY WEIGHT; BONE MARROW SUPPRESSION; CANCER PATIENT; DOSE CALCULATION; EVIDENCE BASED PRACTICE; FIRST PASS EFFECT; HUMAN; MEDICATION ERROR; PERSONALIZED MEDICINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASMS; PHYSIOLOGY; STANDARDS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BODY HEIGHT; BODY SURFACE AREA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; EVIDENCE-BASED MEDICINE; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS;

EID: 84897858063     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.12     Document Type: Review

References (13)

1. Mathijssen, R.H et al. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: Does it make a difference? Oncologist 12, 913-923 (2007.
2. Pinkel, DThe use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res. 18, 853-856 (1958.
3. Sawyer, M. & Ratain, M.J. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest. New Drugs 19, 171-177 (2001.
4. Du Bois, D. & Du Bois, E.F. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 17, 863-871 (1916.
5. Mosteller, R.D. Simplified calculation of bodysurface area. N. Engl. J. Med. 317, 1098 (1987.
6. Baker, S.D. et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J. Natl. Cancer Inst. 94, 1883-1888 (2002.
7. Smorenburg, C.H. et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J. Clin. Oncol. 21, 197-202 (2003.
8. de Graan, A.J. et al. A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform. Clin. Cancer Res. 19, 5210-5217 (2013.
9. Miller, A.A. et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin. Cancer Res. 10, 8325-8331 (2004.
10. Verbraecken, J., Van de Heyning, P., De Backer, W.& Van Gaal, L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 55, 515-524 (2006.
11. Ranchon, F. et al. Chemotherapeutic errors in hospitalised cancer patients: Attributable damage and extra costs. BMC Cancer 11, 478 (2011.
12. Plumridge, R.J. and Sewell, G.J. Dose-banding of cytotoxic drugs: A new concept in cancer chemotherapy. Am. J. Health Syst. Pharm. 58, 1760-1764 (2001.
13. Chatelut, E. et al. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br. J. Cancer 107, 1100-1116 (2012.